Cancer Microbiome Sequencing Market By Size, Share, Trends, Growth, Forecast 2027

Summary

Report Description

The global cancer microbiome sequencing market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing occurrences of cancer and increasing emphasis on the microbiome’s potential in the field of cancer are fueling the growth of the market. Microbiomes are the community of microorganisms that grow or exist on an environment such as saliva, skin layers, oral mucosa of human body and the gastrointestinal tract. Microbiome sequencing is a valuable tool which is used to study and analyze the microbes groups located in or out of the human body to have the better understanding of human microbes. The main aim of microbiome research study is to understand the role and function of microbes in human health and disease. The other factors supporting the market’s growth are, decreasing cost of sequencing, rise in R&D activities, exponential rise in the number of cancer cases worldwide, increasing number of clinical trials, rise in development of novel diagnostic tools based on microbiome for supporting physicians, increasing investments by biotechnology companies, rise in demand for microbiome sequencing services for diagnosis and early detection of the diseases, rise in world population, growing awareness of the use of microbiome sequencing technology, rise in the healthcare expenditure, rising interest of researchers in understanding the role of microbiome in human health and disease, and immense potential for emerging submarkets.

Rising Prevalence of Cancer supports the Market Growth

Growing incidences of cancer such as lung, cervical, breast, skin, throat, and others are augmenting the growth of the market. According to WHO, in 2020, cancer is a major cause of death across the world, reporting for approximately 10 million deaths, or about one in six deaths. The most common cancers are lung, colon and rectum, prostate cancers, and breast. There is a surge in number of cases suffering from cancer caused due to consumption of alcohol, tobacco use, unhealthy eating choices, and sedentary lifestyle. Therefore, need for cancer microbiome sequencing is rising, which in turn, bolster the growth of the market. As per WHO, many cancers can be treated effectively if detected in an early stage.

Increasing Emphasis by Researchers on the Microbiome’s Potential and Rising Support from Biotechnology Companies.

The rising focus on the microbiome’s potential to diagnose, and prevent various cancers is fueling the growth of the market. Various researchers are studying and researching the microbiome’s potential in the field of cancers. Researchers are being supported by biotech companies to unravel insights pertaining to microbiome’s influence on cancer progression and manifestation. Furthermore, the development of cancer microbiome sequencing services and products have aided the research community to create effective strategies for discovering novel cancer biomarkers allied with the microbiome, which could be used for the development of cancer microbiome sequencing products for clinical use.

Download Free Sample Report

Market Segmentation

The global cancer microbiome sequencing market is segmented into component, technology, application, end user, and company. Based on component, the market is divided into kits & assays, software, and services. Based on technology, the market is divided into next generation sequencing and polymerase chain reaction. Based on application, the market is divided into translational research and clinical diagnostics. Based on end user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, hospitals & clinics, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due rising incidences of cancer and rise in R&D activities in the country.

Market Players

Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc. are some of the leading companies operating in the market.

Attribute	Details
Base Year	2021
Historic Data	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, Volume Units and CAGR for 2017-2021 and 2022-2027
Report coverage	Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends
Segments covered	· Component · Technology · Application · End User · Company
Regional scope	North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa
Country scope	United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa; Australia; Turkey; Egypt;
Key companies profiled	Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc.
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global cancer microbiome sequencing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

· Cancer Microbiome Sequencing Market, By Component:

o Kits & Assays

o Software

o Services

· Cancer Microbiome Sequencing Market, By Technology:

o Next Generation Sequencing

o Polymerase Chain Reaction

· Cancer Microbiome Sequencing Market, By Application:

o Translational Research

o Clinical Diagnostics

· Cancer Microbiome Sequencing Market, By End User:

o Biotechnology & Pharmaceutical Companies,

o Academic & Research Institutions

o Hospitals & Clinics

o Others

· Cancer Microbiome Sequencing Market, By Region:

North America

United States
Canada
Mexico

Asia-Pacific

China
India
Japan
Australia
South Korea

Europe & CIS

Germany
France
United Kingdom
Spain
Italy

South America

Brazil
Argentina
Colombia

Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

§ Turkey

§ Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cancer Microbiome Sequencing Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Cancer Microbiome Sequencing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Cancer Microbiome Sequencing Market

5. Voice of Customer

6. Global Cancer Microbiome Sequencing Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Component (Kits & Assays, Software, Services)

6.2.2. By Technology (Next Generation Sequencing v/s Polymerase Chain Reaction)

6.2.3. By Application (Translational Research v/s Clinical Diagnostics)

6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Hospitals & Clinics, Others)

6.2.5. By Company (2021)

6.2.6. By Region

6.3. Market Map

7. North America Cancer Microbiome Sequencing Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Component

7.2.2. By Technology

7.2.3. By Application

7.2.4. By End User

7.2.5. By Country

7.3. North America: Country Analysis

7.3.1. United States Cancer Microbiome Sequencing Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Component

7.3.1.2.2. By Technology

7.3.1.2.3. By Application

7.3.1.2.4. By End User

7.3.2. Canada Cancer Microbiome Sequencing Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Component

7.3.2.2.2. By Technology

7.3.2.2.3. By Application

7.3.2.2.4. By End User

7.3.3. Mexico Cancer Microbiome Sequencing Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Component

7.3.3.2.2. By Technology

7.3.3.2.3. By Application

7.3.3.2.4. By End User

8. Europe Cancer Microbiome Sequencing Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Component

8.2.2. By Technology

8.2.3. By Application

8.2.4. By End User

8.2.5. By Country

8.3. Europe: Country Analysis

8.3.1. France Cancer Microbiome Sequencing Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Component

8.3.1.2.2. By Technology

8.3.1.2.3. By Application

8.3.1.2.4. By End User

8.3.2. Germany Cancer Microbiome Sequencing Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Component

8.3.2.2.2. By Technology

8.3.2.2.3. By Application

8.3.2.2.4. By End User

8.3.3. United Kingdom Cancer Microbiome Sequencing Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Component

8.3.3.2.2. By Technology

8.3.3.2.3. By Application

8.3.3.2.4. By End User

8.3.4. Italy Cancer Microbiome Sequencing Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Component

8.3.4.2.2. By Technology

8.3.4.2.3. By Application

8.3.4.2.4. By End User

8.3.5. Spain Cancer Microbiome Sequencing Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Component

8.3.5.2.2. By Technology

8.3.5.2.3. By Application

8.3.5.2.4. By End User

9. Asia-Pacific Cancer Microbiome Sequencing Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Component

9.2.2. By Technology

9.2.3. By Application

9.2.4. By End User

9.2.5. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China Cancer Microbiome Sequencing Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Component

9.3.1.2.2. By Technology

9.3.1.2.3. By Application

9.3.1.2.4. By End User

9.3.2. India Cancer Microbiome Sequencing Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Component

9.3.2.2.2. By Technology

9.3.2.2.3. By Application

9.3.2.2.4. By End User

9.3.3. Japan Cancer Microbiome Sequencing Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Component

9.3.3.2.2. By Technology

9.3.3.2.3. By Application

9.3.3.2.4. By End User

9.3.4. South Korea Cancer Microbiome Sequencing Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Component

9.3.4.2.2. By Technology

9.3.4.2.3. By Application

9.3.4.2.4. By End User

9.3.5. Australia Cancer Microbiome Sequencing Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Component

9.3.5.2.2. By Technology

9.3.5.2.3. By Application

9.3.5.2.4. By End User

10. South America Cancer Microbiome Sequencing Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Component

10.2.2. By Technology

10.2.3. By Application

10.2.4. By End User

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Cancer Microbiome Sequencing Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Component

10.3.1.2.2. By Technology

10.3.1.2.3. By Application

10.3.1.2.4. By End User

10.3.2. Argentina Cancer Microbiome Sequencing Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Component

10.3.2.2.2. By Technology

10.3.2.2.3. By Application

10.3.2.2.4. By End User

10.3.3. Colombia Cancer Microbiome Sequencing Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Component

10.3.3.2.2. By Technology

10.3.3.2.3. By Application

10.3.3.2.4. By End User

11. Middle East and Africa Cancer Microbiome Sequencing Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Component

11.2.2. By Technology

11.2.3. By Application

11.2.4. By End User

11.2.5. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa Cancer Microbiome Sequencing Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Component

11.3.1.2.2. By Technology

11.3.1.2.3. By Application

11.3.1.2.4. By End User

11.3.2. Saudi Arabia Cancer Microbiome Sequencing Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Component

11.3.2.2.2. By Technology

11.3.2.2.3. By Application

11.3.2.2.4. By End User

11.3.3. UAE Cancer Microbiome Sequencing Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Component

11.3.3.2.2. By Technology

11.3.3.2.3. By Application

11.3.3.2.4. By End User

11.3.4. Turkey Cancer Microbiome Sequencing Market Outlook

11.3.4.1. Market Size & Forecast

11.3.4.1.1. By Value

11.3.4.2. Market Share & Forecast

11.3.4.2.1. By Component

11.3.4.2.2. By Technology

11.3.4.2.3. By Application

11.3.4.2.4. By End User

11.3.5. Egypt Cancer Microbiome Sequencing Market Outlook

11.3.5.1. Market Size & Forecast

11.3.5.1.1. By Value

11.3.5.2. Market Share & Forecast

11.3.5.2.1. By Component

11.3.5.2.2. By Technology

11.3.5.2.3. By Application

11.3.5.2.4. By End User

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

14.1. Illumina, Inc.

14.2. Eurofins Scientific SE

14.3. QIAGEN NV

14.4. Thermo Fischer Scientific, Inc.

14.5. Oxford Nanopore Technologies plc.

14.6. OraSure Technologies, Inc.

14.7. Pacific Biosciences of California, Inc.

14.8. Psomagen, Inc

14.9. Prescient Medicine Holdings, Inc.

14.10. Micronoma Inc.

15. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Global Cancer Microbiome Sequencing Market?

Growing occurrences of cancer and increasing emphasis on the microbiome’s potential in the field of cancer are driving the demand for the global cancer microbiome sequencing market.

Who are the top players operating in the global Cancer Microbiome Sequencing market?

Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc. are the key players operating in the global cancer microbiome sequencing market.

What are the key factors hampering growth for the Global Cancer Microbiome Sequencing Market?

The lack of high complexity testing centers in markets, regulatory challenges for direct-to-consumer (DTC) companies, and existing diagnostic confidence on conventional cancer diagnostics may hamper the growth of the global cancer microbiome sequencing market.

Which region has the highest demand for Cancer Microbiome Sequencing Market?

The Asia-Pacific is expected to register the highest CAGR during the forecast period.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Cancer Microbiome Sequencing Market to be dominated by Rising Incidences of Cancer through 2027

Nov, 2022

Growing focus on the microbiome’s potential in the field of cancers to drive the cancer microbiome sequencing market in the forecast period, 2023-2027.

Buy Now